Publikationen, an denen er mitarbeitet Guillermo Izquierdo Ayuso (61)

2022

  1. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

2020

  1. New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab

    Frontiers in Neurology, Vol. 11

  2. Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab

    Scientific Reports, Vol. 10, Núm. 1

  3. Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

    Neurology and Therapy, Vol. 9, Núm. 2, pp. 443-457

  4. XII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2019 (I)

    Revista de neurologia, Vol. 70, Núm. 10, pp. 379-390

  5. XII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2019 (II)

    Revista de neurologia, Vol. 70, Núm. 11, pp. 417-429

2019

  1. Review of the novelties presented at the 2018 ECTRIMS congress: 11th post-ECTRIMS meeting (II)

    Revista de Neurologia, Vol. 68, Núm. 11, pp. 468-479

  2. Review of the novelties presented at the 2018 ectrims congress: 11th post-ectrims meeting (I)

    Revista de Neurologia, Vol. 68, Núm. 10, pp. 431-441

  3. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

    The Lancet Neurology, Vol. 18, Núm. 9, pp. 845-856

2018

  1. A guide to treating gait impairment with prolonged-release fampridine (Fampyra ® ) in patients with multiple sclerosis

    Neurologia

  2. Review of the novelties from the 2017 ECTRIMS congress, presented at the 10th post-ectrims meeting (I)

    Revista de Neurologia, Vol. 67, Núm. 1, pp. 15-27

  3. Review of the novelties from the 2017 ectrims congress, presented at the 10th post-ectrims meeting (II)

    Revista de Neurologia, Vol. 67, Núm. 2, pp. 50-62

2017

  1. Revisión de las novedades del XXXII Congreso ECTRIMS 2016, presentadas en la IX Reunión Post-ECTRIMS (II)

    Revista de Neurologia, Vol. 65, Núm. 2, pp. 75-84

  2. Revisión de las novedades del XXXII congreso ectrims 2016, presentadas en la ix reunión post-ectrims (I)

    Revista de Neurologia, Vol. 65, Núm. 1, pp. 31-40

  3. Sodium intake and multiple sclerosis activity and progression in BENEFIT

    Annals of Neurology, Vol. 82, Núm. 1, pp. 20-29

  4. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort

    European Journal of Clinical Investigation, Vol. 47, Núm. 2, pp. 158-166

2016

  1. Analysis of plasminogen genetic variants in multiple sclerosis patients

    G3: Genes, Genomes, Genetics, Vol. 6, Núm. 7, pp. 2073-2079

  2. Respuesta al tratamiento con interferón beta en pacientes con esclerosis múltiple. Validación del Rio Score

    Revista de Neurologia, Vol. 63, Núm. 4, pp. 145-150

  3. Revisión de las novedades del XXXI Congreso ECTRIMS 2015, presentadas en la VIII Reunión Post-ECTRIMS

    Revista de Neurologia, Vol. 62, Núm. 12, pp. 559-569

2015

  1. A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis

    Human Molecular Genetics, Vol. 24, Núm. 19, pp. 5619-5627